Activity Dates: 04/24/2020 - 04/24/2023
This course is designed for pharmacists, nurse practitioners or other health care professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.
Attention deficit/hyperactivity disorder (ADHD) is one of the more common psychiatric diagnoses within the pediatric population. While rates may decline with age, a large percentage of these individuals will continue to meet criteria for diagnosis in adulthood.
Within the past five years, a number of new stimulant formulations have entered the market. Given the various formulations, health care providers will benefit from an understanding of the pharmacokinetics and other key parameters, between the newer formulations compared to currently available products. This will allow them to determine the most appropriate product for a given patient.
The role of the pharmacist has expanded and collaborative practice models may now include ADHD management.
Beyond these recently approved agents and expanded pharmacist roles, new guidance has been released regarding the use of 2D6 phenotype to determine initial atomoxetine dose titration. This session will describe how to utilize genetic data and individual patient factors to select the most appropriate ADHD treatment for an individual patient.
You will proceed through the following steps to satisfactorily complete this course:
Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Clayton English, PharmD, BCPS, BCPP, BCGP
View biographical information
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
|
Shari N. Allen, PharmD, BCPP Assistant Professor PCOM-SOP Suwanee, GA No Relevant Financial Relationships to Disclose |
Jennifer Bean, PharmD, BCPS, BCPP |
 Jolene R. Bostwick, PharmD, BCPP, BCPSProgram Administrative Chair Associate Chair & Clinical Associate Professor, Department of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor, MI Educational Grants, Research Grants or Contracts: Grant, Ethel and James Flinn Foundation |
|
Lauren M. Brown, PharmD, BCPP Clinical Pharmacy Specialist, Psychiatry South Texas Veterans Health Care System San Antonio, TX No Relevant Financial Relationships to Disclose |
|
Chelsea N. Carr, PharmD, BCPP Clinical Pharmacist, Psychiatry UPMC Western Psychiatric Hospital Pittsburgh, PA No Relevant Financial Relationships to Disclose |
Andria F. Church, PharmD, BCPP, BCPS |
|
Ericka L. Crouse, PharmD, BCPP, BCGP, FASHP, FASCP Associate Professor VCU School of Pharmacy Richmond, VA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: ASHP - PAM Behavioral Health Committee (volunteer), Editorial Board - The Medical Letter (paid), American Society of Consultant Pharmacists - speak at meetings on GeroPsych topics (paid) |
|
Amber R. Douglass, PharmD, BCPS, BCPP Clinical Pharmacy Specialist - Mental Health VA Tennessee Valley Healthcare System Murfreesboro, TN No Relevant Financial Relationships to Disclose |
|
Kristen N. Gardner, PharmD, BCPP Clinical Pharmacy Specialist - Behavioral Health Kaiser Permanente Colorado Denver, CO No Relevant Financial Relationships to Disclose |
|
Michelle L. Geier, PharmD, BCPP Psychiatric Clinical Pharmacist Supervisor San Francisco Department of Public Health San Francisco, CA No Relevant Financial Relationships to Disclose |
 Robert J. Haight, PharmD, BCPPProgram Committee Chair Clinical Pharmacy Specialist-Psychiatry University of MN Medical Center Minneapolis, MN No Relevant Financial Relationships to Disclose |
|
Suzanne C. Harris, PharmD, BCPP Clinical Assistant Professor/UNC Hospitals Region Experiential Director/Clinical Pharmacist Practitioner UNC Eshelman School of Pharmacy Chapel Hill, NC Educational Grants, Research Grants or Contracts: North Carolina AHEC Campus Innovations Grants |
|
Erin D. Knox, PharmD, BCPP Pharmacy Education Specialist UC Irvine Health Orange, CA No Relevant Financial Relationships to Disclose |
|
Michael Kotlyar, PharmD, MS Associate Professor University of Minnesota Minneapolis, MN No Relevant Financial Relationships to Disclose |
 Rex S. Lott, PharmD, BCPPBCPP Program Director Professor Emeritus of Pharmacy Practice Idaho State University - College of Pharmacy Meridian, ID No Relevant Financial Relationships to Disclose |
|
Megan Maroney, PharmD, BCPP Clinical Associate Professor Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey Long Branch, NJ External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Pharmacy Times - speaker honoraria, Otsuka Pharmaceuticals - Excel Speakers Bureau, Novus Medical Education - consultant/medical writing, PlatformQ Health - speaker honoraria, Specialty Pharma Education Center - speaker honoraria |
Marketa Marvanova, PharmD, BCGP, BCPP, PhD |
 Sarah T. Melton, PharmD, BCPP, BCACP, FASCPRecertification Editorial Board Chair Professor of Pharmacy Practice Gatton College of Pharmacy Johnson City, TN Non-Financial Interests: One Care of Southwest Virginia |
Emma C. Palmer, PharmD, BCPS, BCPP |
|
Melissa C. Palmer, PharmD, BCPS, BCPP Clinical Assistant Professor University of Missouri-Kansas City School of Pharmacy Kansas City, MO No Relevant Financial Relationships to Disclose |
|
Kristina Reinstatler, PharmD, BCPP, MBA Clinical Pharmacy Specialist UC Health University of Cincinnati Medical Center Cincinnati, OH No Relevant Financial Relationships to Disclose |
|
Michael D. Shuman, PharmD, BCPP Staff Pharmacist Central State Hospital Lousiville, KY No Relevant Financial Relationships to Disclose |
|
Sheryl Thedford, PharmD, BCPP, BCPS, PhD Clinical Psychiatric Pharmacist Spring Grove Hospital Center Catonsville, MD No Relevant Financial Relationships to Disclose |
|
Gabriela D. Williams, PharmD, BCPS, BCPP Clinical Pharmacy Specialist, Psychiatry Eskenazi Health Indianapolis, IN External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Indiana University Opioid Use Disorder ECHO Program, Affiliate Faculty, Department of Pharmacy Practice, Purdue University College of Pharmacy, Continuing Education Faculty Reviewer, Purdue University College of Pharmacy |
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Off-label pharmacogenomic screening for psychostimulants (currently not in label packaging indicating pharmacogenomic screening); will briefly mention off-label use of bupropion, desipramine, clonidine IR, guanfacine IR in treatment of ADHD
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
